News & Event
- Home
- News
- News & Event
According to Yonhap News,
(Jeonju=Yonhap News) KAI Biotech, the first research firm of the Jeonbuk R&D Specialized Zone, succeed in attracting investment of KRW 3 billion from venture capital firms.
North Jeolla Province announced that KB Investment and Kolon Investment pledged to invest KRW 1.5 billion respectively in KAI Biotech, a promising research firm with technological competitiveness and growth potential.
KAI Biotech was established through industry-institute-hospital collaboration in 2012 aiming to commercialize patent technology of radiopharmaceuticals developed by the Chonbuk National Univesity and produce dementia diagnostic agents.
Starting from the production of fluorodeoxyglucose radiopharmaceuticals, the research firm plans to produce and distribute dementia diagnostic agents of multi-national companies before ultimately developing new radiopharmaceuticals.
ichong@yna.co.kr
Copyrights Yonhap News. All Rights Reserved.
Source: Yonhap News (Sep. 5, 2016)
** This article was translated from the Korean.